As the development of autoimmunity and on-target/off-tumor effects in patients is a major side effect in immunotherapy, the Her2 model has facilitated the development of safer and more clinically relevant therapies in a physiologically relevant immune-tolerant model. Here, ERBB2 is linked to neoplasm.